Norditropin® National Registry

Protocol Description

The Norditropin® National Registry is a multi-center, open-label, post-marketing surveillance study available to all patients being treated with Norditropin for growth failure associated with an inadequate secretion of growth hormone. Norditropin is a human growth hormone made by recombinant DNA technology. The primary objective of this protocol is to collect information on the long-term safety, growth and pharmo-dynamic response of Norditropin as used in clinical practice in the United States.

Eligibility Criteria

Children of either sex who are being treated with Norditropin for growth failure are eligible to participate.
Boys: All ages
Girls: All ages


Participation will only involve data collection and periodic blood draws, conducted as part of routine patient care. The study will collect and record all medical record information from lab tests, x-rays and clinic visits.
Visits: None beyond normal clinical care
Duration: Until patient is no longer seen in clinic

Status: Open for Enrollment

Source(s) of Support

Novo Nordisk Inc.

Primary Investigator

Oscar Escobar, MD

Contact Information

To get started, please contact:
Ana Diaz, RN
Virginia Stefanick, RN